trending Market Intelligence /marketintelligence/en/news-insights/trending/ck59-e8rqr0v2yw3rijcvw2 content esgSubNav
In This List

Celgene invests in privately held stem cell therapy focused Nohla Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celgene invests in privately held stem cell therapy focused Nohla Therapeutics

Seattle-based privately held Nohla Therapeutics Inc. completed a $45 million series B financing from certain investors, which included Celgene Corp.

Nohla develops off-the-shelf cell therapies for treating cancer and other critical diseases.

The particular round of financing also included Fidelity Management and Research Co., ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.

Nohla intends to use the proceeds to complete ongoing phase 2 trials of its lead product candidate dilanubicel, a stem and progenitor cell therapy designed to provide short-term bone marrow function, to support commercial manufacturing needs and advance its product pipeline.